This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Response Genetics, Inc. Announces Four New Contracts With National PPO Networks

LOS ANGELES, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently closed four new payor contracts with national Preferred Provider Organization ("PPO") networks. The four new provider agreements are with:
  • America's Choice Provider Network, LLC
  • FedMed, Inc.
  • Galaxy Health Network
  • Prime Health Services, Inc.

By entering into these PPO network agreements, the full suite of Response Genetics' precision genetics services are now offered to the health plans, self-insured employers, third party administrators and other clients that participate in these networks. In total, these new contractual relationships allow Response Genetics access to an additional 54 million people spread throughout the United States. With these latest PPO network contracts, Response Genetics has now entered into a total of six PPO network contracts this year opening access to over 135 million Americans.

Response Genetics' predictive genomic testing is primarily targeted to patients battling lung, colon, gastric, and melanoma cancers. The results generated from Response Genetics' testing services provide treating physicians actionable information that guides therapeutic decisions enabling the best therapy on a specific patient's tumor. The precise nature of Response Genetics' services brings a value proposition that is expected to improve patient outcomes, enhance efficiencies and ultimately reduce costs associated with optimal health care delivery.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit .

About America's Choice Provider Network, LLC 

America's Choice Provider Network, LLC ("ACPN") is a National Healthcare Savings Provider Network that has developed its own network and technology. ACPN is dedicated to finding solutions to assist every party in healthcare transactions. ACPN and its experienced team is committed to creating solutions in the healthcare industry as it relates to the millions of claims that fall out-of-network each month.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs